2. Search Result
Search Result
Pathways Recommended: Anti-infection
Results for "

drug-resistant infections

" in MedChemExpress (MCE) Product Catalog:

81

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

9

Peptides

1

Inhibitory Antibodies

5

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1228
    Ribostamycin sulfate
    1 Publications Verification

    Vistamycin sulfate

    		 Antibiotic PDI Infection
    Ribostamycin sulfate (Vistamycin sulfate) is a broad-spectrum aminoglycoside Antibiotic with bactericidal activity against Gram-positive cocci, Gram-negative cocci, bacilli, and drug-resistant strains. Ribostamycin sulfate also acts as an inhibitor of protein disulfide isomerase (PDI), with a binding constant KD of 319 μM for bovine PDI. Ribostamycin sulfate targets bacterial 16S ribosomal RNA and the 30S ribosomal subunit, causing translational misreading and thereby inhibiting bacterial protein synthesis. Ribostamycin sulfate disrupts the integrity of bacterial cell membranes, induces membrane pore formation, and leads to bacterial death. Ribostamycin sulfate can be used in studies related to bacterial infections .
    Ribostamycin sulfate
  • HY-146331
    PC190723

    		Bacterial Infection
    PC190723 is a bacterial cell division protein FtsZ inhibitor (IC50 = 55 nM). PC 190723 prevents cell division. PC190723 has potent and selective bactericidal activity against staphylococci, including methicillin- and multi-drug-resistant Staphylococcus aureus. PC190723 induces nucleated assembly of Bs-FtsZ into single-stranded coiled protofilaments and polymorphic condensates. PC190723 can be studied in anti-bacterial infection research .
    PC190723
  • HY-12638
    Dichlorophen
    1 Publications Verification

    DDM

    		 Environmental Pollutants Fungal Parasite Bacterial Infection
    Dichlorophen is a chlorophenol antimicrobial agent that can destroy the integrity of microbial cell membranes and interfere with the activity of metabolic enzymes. Dichlorophen can covalently bind to the thiol groups of microbial proteins and has broad-spectrum antibacterial, antifungal and anthelmintic activity. Dichlorophen can be used as an antimicrobial agent in the study of drug-resistant bacterial infections .
    Dichlorophen
  • HY-P2460
    SMAP-29

    		Bacterial Fungal Interleukin Related TNF Receptor Infection Inflammation/Immunology
    SMAP‑29 is a cathelicidin antimicrobial peptide with LPS‑binding and anti‑inflammatory properties. SMAP‑29 exerts broad‑spectrum antimicrobial activity against bacteria, fungi and multidrug‑resistant isolates. SMAP‑29 kills pathogens by permeabilizing bacterial membranes, inducing depolarization and cell lysis, and also inhibits inflammatory cytokines while reducing lethality in septic shock and pneumonia models. SMAP-29 can be used for research on bacterial infections, drug-resistant infections, septic shock .
    SMAP-29
  • HY-19487
    Ribocil

    		Bacterial Infection
    Ribocil is a selective inhibitor targeting the bacterial FMN riboswitch, regulating the bacterial riboflavin riboswitch. Ribocil competitively binds to the FMN binding site, mimicking the natural ligand FMN to induce conformational changes in the riboswitch, inhibiting ribB gene expression, reducing riboflavin synthesis, and thus inhibiting bacterial growth. Ribocil strongly inhibits GFP expression (EC50=0.3 μM). Ribocil exhibits in vivo antibacterial activity in a mouse model and can be used to study antibacterial drugs related to drug-resistant bacterial infections and bacterial riboflavin metabolic pathways[1][2].
    Ribocil
  • HY-W040128
    Kanamycins sulfate

    		Antibiotic Autophagy JNK Bcl-2 Family Infection
    Kanamycins sulfate is a blood-brain barrier-permeable JNK1 and Bcl-2 modulator as well as an antibiotic, with broad-spectrum antibacterial, and biofilm-inhibiting activities, and it induces autophagy. Kanamycins sulfate promotes Bcl-2 phosphorylation to upregulate autophagy levels, triggering changes such as mitochondrial swelling and endoplasmic reticulum expansion. Consequently, it causes reversible neuronal damage in the dorsal cochlear nucleus without inducing significant neuronal apoptosis. In the presence of exogenous alanine or glucose, Kanamycins sulfate effectively kills drug-resistant bacteria, restores drug sensitivity of multidrug-resistant bacteria, and alleviates urinary tract and kidney infections in mice. Kanamycins sulfate can be applied to scientific research related to Mycobacterium tuberculosis, salmonellosis, brucellosis, shigellosis, urinary tract infections, and reversible neurotoxicity .
    Kanamycins sulfate
  • HY-W984782
    Flindersine

    		GLUT Bacterial Fungal AMPK PPAR Reactive Oxygen Species (ROS) Apoptosis SOD Infection Metabolic Disease Cancer
    Flindersine is an alkaloid with multiple activities including antibacterial, antifungal, antitumor, and antidiabetic properties. Flindersine increases the activity of antioxidant enzymes, restores the levels of renal biomarkers, and reduces blood glucose, blood lipid, and insulin levels in diabetic rats. Flindersine inhibits the growth of Gram-positive bacteria, Gram-negative bacteria, drug-resistant bacteria, as well as dermatophytes, filamentous fungi, and yeasts. Flindersine reduces the viability of cancer cells and induces apoptosis. Flindersine can be used in research related to breast cancer, type 2 diabetes, bacterial infections, and fungal infections .
    Flindersine
  • HY-P10233A
    SAAP 148 TFA

    		Bacterial Infection
    SAAP 148 TFA is a synthetic antimicrobial peptide (bacteria) that interacts with and disrupts the lipid bilayer of bacterial cytoplasmic membranes, thereby inducing changes in membrane permeability and bacterial death. SAAP 148 TFA kills drug-resistant, multidrug-resistant and persister bacterial strains, inhibits biofilm formation, eliminates established biofilms, and blocks bacterial colonization on implant surfaces. SAAP 148 TFA retains its activity after modification or immobilization, exhibits variable cytotoxicity in different human cell models, and shows reduced efficacy in protein-rich environments. SAAP 148 TFA can be used in infection-related research .
    SAAP 148 TFA
  • HY-103249
    Reutericyclin

    Reutericycline

    		 Bacterial Infection Metabolic Disease
    Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections .
    Reutericyclin
  • HY-151102
    Fabimycin

    		Antibiotic Bacterial Infection
    Fabimycin is a FabI inhibitor with potent antibacterial activity against gram-negative bacteria. Fabimycin is effective against drug-resistant gram-negative Infections in vivo .
    Fabimycin
  • HY-W1127089
    Antifungal agent 136

    		Fungal Cytochrome P450 Interleukin Related Infection Inflammation/Immunology
    Antifungal agent 136 is a CYP51 inhibitor and antifungal agent. Antifungal agent 136 downregulates the expression of interleukin-6 to alleviate inflammatory responses. Antifungal agent 136 exhibits activity against both drug-sensitive and drug-resistant Candida albicans strains. Antifungal agent 136 can be used in the research of fungal infections and inflammatory diseases .
    Antifungal agent 136
  • HY-N14107
    Cinnabarin

    		Bacterial Endogenous Metabolite Infection
    Cinnabarin is a natural phenoxazinone red pigment derived from Pycnoporus sanguineus. Cinnabarin reduces rabies virus infection levels in neuroblastoma cells and causes cytopathic effects on neuroblastoma cell monolayers at high concentrations. Cinnabarin exhibits antibacterial activity against bacteria, with a preference for Gram-positive bacteria and human isolates. Cinnabarin can be used in studies related to rabies and drug-resistant Gram-positive bacteria .
    Cinnabarin
  • HY-177716
    Ciprofloxacin prodrug-1

    		Beta-lactamase Bacterial Infection
    Ciprofloxacin prodrug-1 (Compound 35) is an activated prodrug of β-lactase. Ciprofloxacin prodrug-1 exhibits good antibacterial activity against bacteria containing β-lactase (MIC = 63 nM). After being hydrolyzed by β-lactase, Ciprofloxacin prodrug-1 can release Ciprofloxacin (HY-B0356), thereby inhibiting the activity of DNA gyrase. Ciprofloxacin prodrug-1 can be used to study infections caused by enzyme-producing drug-resistant bacteria (such as uropathogenic Escherichia coli) .
    Ciprofloxacin prodrug-1
  • HY-P10233
    SAAP 148

    		Bacterial Infection
    SAAP 148 is a synthetic antimicrobial peptide (bacteria) that interacts with and disrupts the lipid bilayer of bacterial cytoplasmic membranes, thereby inducing changes in membrane permeability and bacterial death. SAAP 148 kills drug-resistant, multidrug-resistant and persister bacterial strains, inhibits biofilm formation, eliminates established biofilms, and blocks bacterial colonization on implant surfaces. SAAP 148 retains its activity after modification or immobilization, exhibits variable cytotoxicity in different human cell models, and shows reduced efficacy in protein-rich environments. SAAP 148 can be used in infection-related research .
    SAAP 148
  • HY-172734
    FG-2101

    		Bacterial Infection
    FG-2101 is a selective and orally active non-hydroxamate LpxC inhibitor with an IC50 of ~1 nM. FG-2101 exhibits exquisite selectivity over other bacterial and human metalloenzymes. FG-2101 can be used for the study of Gram-negative bacteria infections including drug-resistant strains .
    FG-2101
  • HY-178347
    Debio 1453

    		Bacterial Infection
    Debio 1453 is a bactericidal FabI inhibitor potent against N. gonorrhoeae (IC50 = 0.6 nM), including drug-resistant strains. Debio 1453 demonstrates a low propensity for resistance selection and is effective in eradicating both planktonic and intracellular bacteria through a mechanism of concurrently inhibiting FabI and engaging the non-mutable NADH cofactor. Debio 1453 clears antibiotic-resistant N. gonorrhoeae infection in a murine vaginal model. Debio 1453 can be used for gonorrhoea research .
    Debio 1453
  • HY-125356
    ETX0282

    		Beta-lactamase Infection
    ETX0282 is an orally active prodrug, with its active form being ETX1317. ETX0282 and ETX1317 are β-lactamase inhibitors of the dioxolane-dibenzo-p-heptane (DBO) type. ETX0282 exhibits high stability during intestinal absorption and can be efficiently converted into ETX1317 in the liver. ETX0282 alone has no bactericidal activity, but in a mouse model of neutropenic thigh infection, it can significantly reduce bacterial load when used in combination with Cefpodoxime Proxetil (HY-N7101). ETX0282 can be used for the study of infections caused by drug-resistant Gram-negative bacteria .
    ETX0282
  • HY-124952
    iKIX1

    		Fungal Infection
    iKIX1 is an antifungal agent and resensitizes drug-resistant C. glabrata to azole antifungals in vitro. iKIX1 inhibits the interaction between the KIX domain of the mediator subunit CgGal11A and the activation domain of CgPdr1, the IC50 and Ki values are 190.2 μM and 18 μM, respectively. iKIX1 is used for the study of multidrug resistance and C. glabrata infection .
    iKIX1
  • HY-105048A
    Omiganan pentahydrochloride

    		Bacterial Infection
    Omiganan pentahydrochloride is a cationic peptide compound with a broad antibacterial profile. Omiganan pentahydrochloride is capable of inhibiting a variety of bacteria, including yeast, and is active against both gram-positive and gram-negative bacteria. Omiganan pentahydrochloride is able to interact with the bacterial cell membrane, causing the destruction of the cell membrane and the death of the bacteria. Omiganan pentahydrochloride can be used for the study of antimicrobial activity against pathogens commonly associated with catheter-associated infections, including strains with drug-resistant phenotypes .
    Omiganan pentahydrochloride
  • HY-W264454
    Antibacterial agent 303

    		Bacterial Infection
    Antibacterial agent 303 (compound 3) is an antibacterial agent exhibiting potent antibacterial activity against MDR strains, with MICs of 10 and 100 µg/mL against Pseudomonas aeruginosa MDR1 and Staphylococcus aureus MDR strains, respectively. Antibacterial agent 303 displays strong binding affinities to E. coli DNA gyrase and Candida albicans lanosterol 14α-demethylase. Antibacterial agent 303 can be used for drug-resistant infections research .
    Antibacterial agent 303
  • HY-155283
    Zndm19

    		Beta-lactamase Bacterial Infection
    Zndm19 is a New Delhi Metallo-β-lactamase-1 (NDM-1) inhibitor. Zndm19 can be used for the research of drug-resistant bacterial infections .
    Zndm19
  • HY-178504
    Lug-15

    		Bacterial Infection
    Lug-15 is a rapid bactericidal agent. Lug-15 exhibits strong antibacterial activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains. Lug-15 rapidly kills bacteria primarily through membrane disruption and had a very low propensity to induce bacterial resistance. Lug-15 demonstrates low hemolytic toxicity and significant therapeutic potential in various infection models. Lug-15 can be used for research on combating infections caused by multi-drug resistant bacteria .
    Lug-15
  • HY-P5550
    Urumin

    		Influenza Virus Infection
    Urumin has antiviral activity against the human influenza A virus. Urumin inhibits the growth of PR8 influenza virus (IC50: 3.8 μM). Urumin targets the conserved stalk of H1 hemagglutini, and is effective at neutralizing drug-resistant H1 influenza viruses. Urumin protects naive mice from lethal influenza infection .
    Urumin
  • HY-173478
    OSUAB-0284

    		Topoisomerase Bacterial Antibiotic Infection
    OSUAB-0284 is a bacterial topoisomerase inhibitor. OSUAB-0284 has significant anti-staphylococcal activity, especially against methicillin-resistant Staphylococcus aureus (MRSA). OSUAB-0284 exerts its antibacterial effect by inhibiting bacterial topoisomerase. OSUAB-0284 can be used to study infections caused by drug-resistant bacteria such as MRSA .
    OSUAB-0284
  • HY-146811
    HSGN-94

    		Bacterial Inflammation/Immunology
    HSGN-94 is a potent antimicrobial agent with lipoteichoic acid (LTA) biosynthesis inhibition. HSGN-94 inhibits drug-resistant Gram-positive bacteria with MIC values of 0.25-2 μg/mL. HSGN-94 inhibits biofilm formation of MRSA and Vancomycin-resistant Enterococci. HSGN-94 also inhibits pro-inflammatory cytokines, exhibits in vivo efficacy in an MRSA murine wound infection model .
    HSGN-94
  • HY-102009
    BB-83698

    		Bacterial Infection
    BB-83698 is a peptide deformylase (PDF) inhibitor. BB-83698 exhibits potent in vitro activity against Streptococcus pneumoniae, with a minimum inhibitory concentration (MIC) range of 0.06-0.25μg/mL. BB-83698 elevates the survival rate of mice regardless of whether the infecting strain carries resistance mechanisms. BB-83698 can be used for the study of diseases related to drug-resistant Streptococcus pneumoniae infections .
    BB-83698
  • HY-P11027
    Thiazoplanomicin

    		Bacterial Antibiotic Infection
    Thiazoplanomicin (Compound 1) is a thiazolyl peptide antibiotic. Thiazoplanomicin can be isolated from the leaf-litter actinomycete Actinoplanes sp. MM794L-181F6. Thiazoplanomicin has potent antimicrobial activities against gonococcal strains (especially drug-resistant strains) and Gram-positive bacterium with MICs of 31.2-125 and 0.5-15.6 ng/mL, respectively. Thiazoplanomicin has no antibacterial activity against E.coli. Thiazoplanomicin can be used for bacterial infections research .
    Thiazoplanomicin
  • HY-179389
    XDS-23

    		Bacterial Glutathione S-transferase Elastase Infection
    XDS-23 is a selective biofilm inhibitor with an IC50 of 1.26 µM against Pseudomonas aeruginosa. XDS-23 exerts a dual inhibitory effect on the LasI/LasR System (las) and Pseudomonas Quinolone Signal System (pqs). XDS-23 suppress the production of key virulence factors including elastase, pyocyanin, and extracellular polysaccharides. XDS-23 exhibits synergistic antibacterial activity and can enhance the efficacy of multiple antibiotics in both in vitro and in vivo models, while maintaining a favorable safety profile. XDS-23 can be employed for research in combating biofilm-mediated drug-resistant P. aeruginosa infections .
    XDS-23
  • HY-19932
    MK-2748

    		HCV Protease HCV Infection
    MK-2748 is a hepatitis C virus (HCV) NS3/4a protease inhibitor. MK-2748 exhibits broad-spectrum and potent antiviral activity, with nanomolar-level activity against all genotypes (gt1a-gt6) (IC₅₀ < 0.115 nM), showing only slightly weaker activity against gt3a (1.212 nM), and maintaining high inhibitory activity against drug-resistant mutant strains such as gt1b R155K (IC₅₀ = 0.032 nM) and D168Y (IC₅₀ = 0.057 nM). MK-2748 can be used in the research of HCV infection .
    MK-2748
  • HY-P10975
    P9R

    		SARS-CoV Influenza Virus Enterovirus Infection
    P9R is an antiviral peptide. P9R has broad-spectrum antiviral activities against the coronaviruses (SARS-CoV-2, MERS-CoV and SARS-CoV), A(H1N1)pdm09, A(H7N9) virus, and rhinovirus. P9R directly binds to viruses and inhibits virus-host endosomal acidification. P9R significantly protects mice from A(H1N1)pdm09 infection without generating drug-resistant virus. P9R can be used for pH-dependent respiratory viruses research .
    P9R
  • HY-151416
    Chitin synthase inhibitor 6

    		Fungal Infection
    Chitin synthase inhibitor 6 (compound 9b) is a potent chitin synthase (CHS) inhibitor with an IC50 value of 0.21 mM. Chitin synthase inhibitor 6 has broad-spectrum antifungal activity against drug-resistant fungi. Chitin synthase inhibitor 6 can be used in the research of fungi infection .
    Chitin synthase inhibitor 6
  • HY-151417
    Chitin synthase inhibitor 7

    		Fungal Infection
    Chitin synthase inhibitor 7 (compound 9c) is a potent chitin synthase (CHS) inhibitor with an IC50 value of 0.37 mM. Chitin synthase inhibitor 7 has broad-spectrum antifungal activity against drug-resistant fungi. Chitin synthase inhibitor 7 can be used in the research of fungi infection .
    Chitin synthase inhibitor 7
  • HY-168108
    Antifungal agent 115

    		Fungal Infection
    Antifungal agent 115 (compound 8n) is a non-competitive chitin synthase (CHS) inhibitor with an IC50 of 93 μM. Antifungal agent 115 demonstrates good selectivity and broad-spectrum antifungal activity, exhibiting significant efficacy against drug-resistant fungi. Antifungal agent 115 can be utilized in fungi infection research .
    Antifungal agent 115
  • HY-178952
    Anti-infective agent 12

    		Bacterial Infection
    Anti-infective agent 12 (Compound A09) is a competitive inhibitor of type I signal peptidease (SPase I), with an IC50 of 4.475 μM and a Kd of 16.3 μM. Anti-infective agent 12 has the ability to disrupt bacterial membranes and remove biofilms. Anti-infective agent 12 exhibits potent bactericidal activity against Gram-positive bacteria, with MIC values of 4, 4, 8, and 8 μg/mL for Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, and Streptococcus suis, respectively. Anti-infective agent 12 remains effective against multi-drug resistant strains, but has weaker activity against Gram-negative bacteria (such as Escherichia coli and Salmonella), with MIC values > 64 μg/mL. Anti-infective agent 12 has low hemolytic activity and shows significant efficacy in mouse skin infection models .
    Anti-infective agent 12
  • HY-157045
    ATP Synthesis-IN-1

    		ATP Synthase Infection
    ATP Synthesis-IN-1 (Compound 4), quinoline derivative, is a potent inhibitor of PA ATP synthesis activity. ATP Synthesis-IN-1 has PA ATP synthesis inhibition with IC50 value of 11.1μg/mL. ATP Synthesis-IN-1 also has antibacterial activity. ATP Synthesis-IN-1 can be used for the research of drug-resistant PA infection .
    ATP Synthesis-IN-1
  • HY-151420
    Chitin synthase inhibitor 10

    		Fungal Infection Cancer
    Chitin synthase inhibitor 10 is a chitin synthase inhibitor. Chitin synthase inhibitor 10 shows excellent chitin synthase inhibitory activity with an IC50 value of 0.11 mM. Chitin synthase inhibitor 10 also is an antifungal agent and has significantly antifungal activity against drug-resistant fungal variants, such as C. albicans and C. neoformans. Chitin synthase inhibitor 10 can be used for the research of invasive fungal infections (IFIs) .
    Chitin synthase inhibitor 10
  • HY-151422
    Chitin synthase inhibitor 12

    		Fungal Infection Cancer
    Chitin synthase inhibitor 12 is a chitin synthase inhibitor. Chitin synthase inhibitor 12 shows excellent inhibitory activity with an IC50 value of 0.16 mM. Chitin synthase inhibitor 12 also is a broad-spectrum antifungal agent and has significantly antifungal activity against drug-resistant fungal variants, such as C. albicans and C. neoformans. Chitin synthase inhibitor 12 can be used for the research of invasive fungal infections (IFIs) .
    Chitin synthase inhibitor 12
  • HY-163030
    LasB-IN-1

    		Elastase NF-κB p38 MAPK Bacterial Infection Inflammation/Immunology
    LasB-IN-1 (compound 5f) is a potent and orally active inhibitor of LasB (IC50 = 8.7 μM). LasB-IN-1 effectively attenuates elastase production and biofilm formation by P. aeruginosa while alleviating the inflammatory response through downregulating MAPK and NF-κB pathways. LasB-IN-1 is potential to be a novel anti-infective candidate against drug-resistant infections .
    LasB-IN-1
  • HY-176210
    CYP51-IN-24

    		Fungal Cytochrome P450 Infection
    CYP51-IN-24 (Compound 22) is a Sterol 14α-Demethylase (CYP51) inhibitor. CYP51-IN-24 exhibits potent inhibitory activity against wild-type and drug-resistant fungi. CYP51-IN-24 inhibits ergosterol biosynthesis by binding to the fungal CYP51 enzyme. CYP51-IN-24 can be used in research and drug development against drug-resistant fungal infections .
    CYP51-IN-24
  • HY-P10526
    CRAMP (1-39)

    		Bacterial Infection
    CRAMP (1-39) is an antimicrobial peptide. CRAMP (1-39) has shown potent bactericidal effects against multiple strains of Neisseria meningitidis in vitro. CRAMP (1-39) can be used to study drug-resistant bacterial infections .
    CRAMP (1-39)
  • HY-P991273
    MP196

    		Antibiotic Bacterial Infection
    MP196 is a cationic hexapeptide antibiotic targeting the bacterial cytoplasmic membrane, which exerts rapid bactericidal activity by disrupting membrane integrity, inhibiting cell respiration and cell wall synthesis. MP196 is promising for research of drug-resistant bacterial infections .
    MP196
  • HY-172895
    Quorum sensing-IN-10

    		Bacterial Infection Inflammation/Immunology
    Quorum sensing-IN-10 (10p), an antibacterial synergist, shows significant inhibition of P. aeruginosa virulence, biofilm, and motility, with low toxicity. Quorum sensing-IN-10 (10p) can be used in the research for drug-resistant Pseudomonas aeruginosa infections .
    Quorum sensing-IN-10
  • HY-D2988
    BIN-3

    		Fluorescent Dye Bacterial Infection
    BIN-3 is a novel near-infrared fluorescent probe. BIN-3 has excellent biocompatibility, no cytotoxicity, and no hemolysis. BIN-3 can be used for highly sensitive and selective imaging of drug-resistant bacterial infections expressing β-lactam enzymes in live mice .
    BIN-3
  • HY-172676
    GW461484A

    		Fungal Casein Kinase Infection
    GW461484A is a small-molecule inhibitor targeting Candida albicans Yck2, with an IC50 of 0.11 µM. It exhibits antifungal activity against C. albicans with a MIC80 of 12.5 µM. GW461484A holds potential for research on fungal diseases, such as drug-resistant Candida infections .
    GW461484A
  • HY-114956
    AT-61

    		HBV Infection
    AT-61 is a non nucleoside HBV replication inhibitor. AT-61 prevents the capsid formation of pre genomic RNA, resulting in the production of empty capsids. AT-61 has the activity of drug-resistant mutant strains. AT-61 can be used for research on hepatitis B virus infection .
    AT-61
  • HY-178985
    HIV-1-IN-90

    		HIV Infection
    HIV-1-IN-90 is a potent HIV inhibitor. HIV-1-IN-90 exhibits potent inhibitory activity against multiple drug-resistant HIV-1 strains with EC50s of 1.5-31 nM. HIV-1-IN-90 has good security. HIV-1-IN-90 can be used for research on HIV virus infection .
    HIV-1-IN-90
  • HY-122209
    DVR-01

    		HBV Infection
    DVR-01 is a HBV inhibitor with EC50 values of 1.7 and 1.6 μM in AML12HBV10 and HepDES19 cells, respectively. DVR-01 shows antiviral activity against drug-resistant HBV mutants with EC50s of 2.403-3.273 μM. DVR-01 can be used for the research of HBV infection and related diseases .
    DVR-01
  • HY-12638R
    Dichlorophen (Standard)

    DDM (Standard)

    		 Reference Standards Bacterial Fungal Parasite Infection
    Dichlorophen (Standard) is the analytical standard of Dichlorophen (HY-12638). This product is intended for research and analytical applications. Dichlorophen is a chlorophenol antimicrobial agent that can destroy the integrity of microbial cell membranes and interfere with the activity of metabolic enzymes. Dichlorophen can covalently bind to the thiol groups of microbial proteins and has broad-spectrum antibacterial, antifungal and anthelmintic activity. Dichlorophen can be used as an antimicrobial agent in the study of drug-resistant bacterial infections .
    Dichlorophen (Standard)
  • HY-B0368C
    epi-D-Captopril

    epi-D-SQ 14225

    		 Beta-lactamase Infection
    epi-D-Captopril (epi-D-SQ 14225) is a stereoisomer of Captopril (HY-B0368) and an inhibitor of metallo-β-lactamases (MBLs). The IC50 values of epi-D-Captopril against NDM-1, IMP-1, and VIM-2 are 64 μM, 173 μM, and 5.5 μM, respectively. epi-D-Captopril is expected to be used in the research of diseases caused by MBLs-related drug-resistant bacterial infections .
    epi-D-Captopril
  • HY-117746
    KSK120

    		Bacterial Infection
    KSK120 is a potent inhibitor of drug-resistant infections with specific activity against Chlamydia trachomatis (C. trachomatis). KSK120 inhibits the developmental cycle of C. trachomatis, thereby reducing the infectivity of progeny bacteria. KSK120 targets the glucose-6-phosphate (G-6P) metabolic pathway of C. trachomatis, showing its potential application in antimicrobial inhibition. The mechanism of KSK120 may involve inhibition of the transcriptional machinery, which provides new ideas for the development of specific drugs against C. trachomatis infection .
    KSK120

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: